Chapter
1: Major Trends Affecting the Biotech & Genetics Industry
|
1 |
|
1) A Short History of Biotechnology |
1 |
|
2) The State of the Biotechnology Industry
Today |
2 |
|
3) New Money Pours into Biotech Firms |
5 |
|
4) Major Drug Companies Bet on Partnerships
With Smaller Biotech Research
Firms |
5 |
|
5) From India to Singapore to Russia, Nations
Compete Fiercely in Biotech
Development |
6 |
|
6) Gene Therapies and Patients’ Genetic
Profiles Promise a Personalized
Approach
to Medicine |
7 |
|
7) New Kinase Inhibitors Are Breakthrough
Drugs for Cancer Treatment—Many
More
Will Follow |
8 |
|
8) Systems Biology May Lead to Faster, More
Cost-Effective Drug Development |
8 |
|
9) Pharmaceutical Costs Soars in U.S., Controversy
over Drug Prices Rages On |
10 |
|
10) Stem Cells—Controversy in the U.S.
Threatens to Leave America Far Behind
in
the Research Race |
12
|
|
11) Stem Cell Funding Trickles at the Federal
Level While California Creates
Funding
of Its Own |
13 |
|
12) Stem Cells—Therapeutic Cloning
Techniques Advance |
14 |
|
13) Stem Cells—A New Era of Regenerative
Medicine Looms |
15 |
|
14) Nanotechnology and Information Technologies
Converge with Biotech |
16 |
|
15) Agricultural Biotechnology Scores Breakthroughs
but Causes Controversy |
16 |
|
16) Breakthrough Drug Delivery Systems Evolve |
18 |
|
17) Biogenerics are in Limbo in the U.S. |
18 |
|
18) HapMap Project Moves Ahead |
18 |
|
19) BioShield Promises $5.6 Billion to Counter
Potential Bioterror Attacks
in
the U.S. |
19
|
|
20) Ethical Issues Abound |
19 |
|
21) Technology Discussion—Genomics |
19 |
|
22) Technology Discussion—Proteomics |
20 |
|
23) Technology Discussion—Microarrays |
20 |
|
24) Technology Discussion—DNA Chips |
20 |
|
25) Technology Discussion—SNPs (“Snips”) |
21 |
|
26) Technology Discussion—Combinatorial
Chemistry |
21 |
|
27) Technology Discussion—Vaccines |
21 |
|
28) Technology Discussion—Synthetic
Biology |
21 |
|
29) Technology Discussion—Recombinant
DNA |
22 |
|
30) Technology Discussion—Polymerase
Chain Reaction (PCR) |
22 |
| Chapter
2: Biotech & Genetics Industry Statistics
|
23 |
|
A Closer Look at the Drug Discovery and Development
Process |
24 |
|
Annual Percent Change in U.S. Research &
Development Spending by Research-Based Pharmaceutical Companies,
1980-2004 |
24
|
|
Average Salaries in the U.S. Pharmaceutical
and Biotechnology Industries: 2005 |
25 |
|
Domestic R&D Spending as a Percentage
of Domestic Sales, U.S. Research-Based Pharmaceutical Companies:
1970-2004
|
26
|
|
Generics' Share of the U.S. Drug Market 1984-2004 |
27 |
|
Global Agricultural Biotech At A Glance,
2004 |
28 |
|
Global R&D Investments by Research-Based
Pharmaceutical Companies:
1970-2004 |
29
|
|
Largest Global Pharmaceutical Companies |
30 |
|
New U.S. Biotech Drug, Vaccine and Indication
Approvals, 1982-2004 |
31 |
|
Profile of U.S. Public Biotech Companies,
2000-2004 |
32 |
|
Total U.S. Biotechnology Patents Granted
Per Year, 1989-2004 |
33 |
|
U.S. Biotech Industry Financings, 1996-2004 |
34 |
|
U.S. Drug and Biopharmaceutical Development
Times, 1985-2004 |
35 |
|
U.S. Drug Discovery and Approval Process |
36 |
|
U.S. FDA Approval Times for New Drugs, 1993-2004 |
37 |
|
U.S. FDA Approval Times for New Molecular
Entities (NMEs*), 1993-2004 |
38 |
|
U.S. National Science Foundation Biological
Sciences Research Funding,
2003-2005 |
39
|
|
U.S. Pharmaceutical R&D Spending Versus
Number of New Drug Approvals (NMEs*), 1993-2004 |
40
|
